The trigemino-cerebrovascular system {#Sec1}
====================================

Pain-sensitive structures such as the intracranial vessels and the meninges, especially the dura mater, are supplied with sensory nerve fibers. In fact they are innervated by the ophthalmic ramus of the first branch of the trigeminal nerve that arises from pseudounipolar neurons located in the trigeminal ganglion. Those neurons project onto second order sensory neurons in the trigmenial nucleus caudalis (TNC) in the brain stem and its related extensions down to the C2-level called the trigeminocervical complex \[[@CR1]\]. From this region a signal is transmitted to the ventroposterior thalamus leading to activation in cortical areas, including frontal cortex, insulae and cingulate cortex. This results in the experience of pain (Fig. [1](#Fig1){ref-type="fig"}). In addition, a migraine active region has been pointed out in the brainstem by using positron emission tomography (PET) \[[@CR2]--[@CR4]\]. Thus, an involvement of the trigemino-cerebrovascular system in the transmission of nociceptive information to the central nervous system is a viable position. Fig. 1In migraine attacks, sensory nerves, which innervate the cerebral blood vessels, are activated to antidromically release calcitonin gene-related peptide. They originate from the first branch of the trigeminal nerve that arises from pseudounipolar neurons located in the trigeminal ganglion (*TG*). Those neurons project onto second order sensory neurons in the trigeminal nucleus caudalis (*TNC*) from where a signal is transmitted to the cortex

The trigemino-cerebrovascular reflex {#Sec2}
====================================

There is a dense supply of CGRP-containing nerve fibers originating in the first division of the trigeminal ganglion that innervate intracranial vessels. Experimental studies have shown that induction of vasoconstriction provoked rapid normalization of the vascular tone due to----in part----reflex activation of the trigeminal nerve. Vasoconstriction triggers an antidromic release of sensory trigeminal neuropeptides, mainly CGRP, being a strong intracranial dilatator \[[@CR5], [@CR6]\]. After denervation there is no alteration in the contractile response of the vessel but the time to attain initial basal tone is markedly prolonged. This is of importance as headache may be initiated by a spreading wave of depression of cortical neurons resulting in contraction of some parts of the cerebral circulation. This phenomenon has now been shown in man \[[@CR7]\] and could activate the trigeminal vascular system to release CGRP to reestablish the vascular tone. Thus, the trigemino-cerebrovascular reflex is probably part of a counter-balancing system, which is able to mediate dilatation of brain vessels and sustain cerebral blood flow \[[@CR8]\]. This may assure the maintenance of local brain blood flow within normal limits as the cerebral circulation requires high and constant flow. Activation of the neurons in the trigeminal ganglion leads on the other hand to an activation of neurons in the trigeminocervical complex that project to the central nervous system (CNS) and mediate the central aspects of pain \[[@CR1], [@CR9]\].

Calcitonin gene-related peptide {#Sec3}
===============================

CGRP is a neuropeptide consisting of 37 amino acids and is predominantly expressed in the nervous system. It originates from the calcitonin gene encoding calcitonin and CGRP depending upon alternative splicing.

Histochemical studies of cerebral perivascular nerve fibers and human trigeminal ganglia revealed that almost half of the cell bodies contain CGRP \[[@CR10], [@CR11]\]. Although many other signal molecules are located in the trigeminal ganglion, CGRP is the most abundant in man \[[@CR12]\] and can be seen as a marker for trigeminal activity. Furthermore it is the only transmitter reliably released in acute migraine attacks at present. There was a marked increase in CGRP levels during migraine attacks, but no changes could be observed for other neuropeptides such as vasoactive intestinal peptide (a marker for parasympathetic activity), neuropeptide Y (sympathetic activity) and substance P (sensory activity) when their levels were analyzed in the cranial venous outflow during migraine attacks \[[@CR8], [@CR13]\].

In migraine attacks elicited within clinical studies by administration of nitroglycerin a good correlation has been described between increased levels of CGRP and the intensity of the headache \[[@CR14], [@CR15]\]. But it is noteworthy to mention that nitroglycerin elicits head pain, but not always genuine migraine attacks. There may be a need for the subject to be in a "prone phase", where the trigemino-cerebrovascular system might be hyper-reactive as it was demonstrated in cluster headache \[[@CR16]\].

Triptans {#Sec4}
========

The increased cranial venous levels of CGRP observed in conjunction with migraine attacks thus indicate activation of the trigeminal system. Administration of sumatriptan----belonging to the highly effective anti-migraine drugs called triptans or 5-HT~1B/1D~ agonists-results in alleviation of the headache and normalization of the cranial venous CGRP levels \[[@CR8]\]. They are thought to act mainly as powerful vasoconstrictors of cerebral vessels via 5-HT~1B~ receptors, which have been shown to be expressed in the medial smooth muscle cell layer of the human middle meningeal \[[@CR17]\] and cerebral arteries \[[@CR18]\].

In addition, triptans may bind to presynaptic 5-HT~1B/1D~ receptors on trigeminal afferents to inhibit nerve activity and hence reduce CGRP release. 5-HT~1B/1D~ receptors were found on trigeminal sensory fibers \[[@CR19]\], trigeminal ganglion cells \[[@CR20]\] and in the trigemino-cerebrovascular system in man \[[@CR21]\]. Furthermore, the 5-HT~1B/1D~ receptors were co-localized with CGRP in the human trigeminal ganglion \[[@CR20]\].

Autoradiographic studies using labeled zolmitriptan confirmed the presence of 5-HT~1B/1D~ receptors in certain brain stem nuclei that are involved in cranial nociceptive processing \[[@CR22]\] and are likely to be activated during migraine.

Thus, it can be presumed that a potential relaxation of intracranial blood vessels during migraine attacks can be normalized by triptans, which activate the cerebrovascular 5-HT~1B~ receptors and thereby cause vasoconstriction. By stimulating 5-HT~1B/1D~ receptors, triptans inhibit the release of CGRP from the perivascular nerve terminals and the trigeminal ganglion cells. Activation of 5-HT~1B/1D~ receptors at the level of the CNS (trigeminal nucleus caudalis) may interrupt central aspects of the headache process.

Recently the relationship between pharmacokinetic and pharmacodynamic aspects of triptans in migraine was investigated. It has been observed that subcutaneous administration of sumatriptan is more effective than oral application. The difference in efficacy is most likely due to the rapid initial rise in plasma level after subcutaneous administration \[[@CR23]\]. Furthermore migraine attacks may influence gastric stasis leading to delayed absorption of drugs \[[@CR24], [@CR25]\]. Thus, to increase efficacy of treatment, attention should be paid to the development of migraine drugs, which can be quickly absorbed.

Triptans cause sometimes cardiovascular adverse effects as they also act as constrictors in coronary arteries. But triptans are considered as more powerful vasoconstrictors in human isolated cerebral arteries than in coronary arteries. They are at least threefold more potent \[[@CR26]\]. The reason for the higher potency and efficiency of triptans in intracranial arteries could be due to at least three differences. First there is a higher number of 5-HT~1B~ receptors in those vessels compared to peripheral arteries \[[@CR18], [@CR27]\]. Secondly there are few, if any, 5-HT~2A~ receptors in intracranial vessels whereas the 5-HT~2A~ receptor population dominates in coronary arteries \[[@CR27]\]. Thirdly, there might be potential differences in coupling of the 5-HT~1B~ receptors between cerebral and coronary arteries. In consideration of the fact that triptans are weak constrictors in coronary arteries \[[@CR28], [@CR29]\] and have little impact on coronary blood flow, the clinical consequences in healthy subjects are minor. However, small contractions may anyhow have proportionally greater impact in diseased artery with luminal narrowing. Triptans are hence contra-indicated in patients with known cardiovascular disease.

Sensitization in migraine {#Sec5}
=========================

Treatment with triptans achieves good results in patients suffering from sensitization. Sensitization is defined as an increased afferent activity in response to an unchanged stimulus \[[@CR30]\] and both peripheral and central sensitization may play a role in migraine attacks. Peripheral sensitization of meningeal perivascular nociceptors arising from trigeminal neurons can clinically explain phenomena like intracranial hypersensitivity (worsening pain during physical activity) and the throbbing element in migraine pain. This may be due to normally innocuous meningeal nociceptors becoming hyper-responsive to rhythmic fluctuation in intracranial pressure that is produced by normal arterial pulsations \[[@CR31], [@CR32]\].

Central sensitization of nociceptive second order neurons in the trigeminocervical complex can be the reason for extracranial tenderness and cutaneous allodynia. The latter is an abnormal sensory state in which otherwise innocuous stimuli are sensed as painful \[[@CR31]\].

Two-thirds of patients develop allodynia during or even after a migraine attack \[[@CR33]\]. Based on clinical studies new guidelines for triptan treatment in migraine has been established. They include that allodynia-free patients can receive good results from triptan treatment at any time during the migraine attack. Furthermore, patients suffering from allodynia can expect excellent results from triptans before allodynia gets established. Therefore they should take triptans as early as possible during the attack. After the onset of allodynia, migraineurs can still benefit from triptans, but pain relief may be incomplete \[[@CR34]--[@CR36]\].

However, a slightly different view has been expressed in a recent study \[[@CR37]\]. After subcutaneous administration of sumatriptan, there was no difference in alleviation of migraine pain irrespective if the drug was given early or late. Therefore, it was suggested that the sensitization is of minor importance and that the relatively poor effect of sumatriptan late in migraine attacks is primarily due to gastric stasis \[[@CR37]\].

CGRP receptors {#Sec6}
==============

Local vasodilatation and release of CGRP from the vascular nerve fiber endings----caused by electrical field stimulation or capsaicin treatment \[[@CR38], [@CR39]\]----are attenuated by administration of triptans, but also by application of CGRP receptor blockers \[[@CR40]\]. The proof that CGRP plays a key role in migraine was provided by demonstrating that the potent CGRP receptor antagonist olcegepant (BIBN4096) could abort acute migraine attacks to a comparable degree as sumatriptan \[[@CR41], [@CR42]\]. In addition, CGRP receptors are located at several sites, which play an important role during migraine, including the cerebrovasculature \[[@CR43]--[@CR45]\], the trigeminocervical complex within the brainstem \[[@CR46]\] and the trigeminal ganglion \[[@CR47]\].

Functional CGRP receptors consist of three components, namely a seven-transmembrane domain G-protein coupled receptor called calcitonin receptor-like receptor (CLR), a receptor activity-modifying protein (RAMP) and a receptor component protein (RCP). CLR shares 55% sequence identity with the calcitonin receptor. Co-expression of CLR with RAMP1 composes the CGRP receptor, while co-expression of CLR with either RAMP2 or RAMP3 represents the adrenomedullin (AM) receptor or possibly a combined receptor (CGRP and AM). Apart from contributing to the receptor specificity, RAMP1 is required for glycosylation and transport of CLR to the plasma membrane \[[@CR48]--[@CR50]\]. In addition, RAMP1 seems to be functionally rate limiting for CGRP receptor activity in the trigeminovascular system. It was proposed that elevated RAMP1 expression could sensitize the trigeminal ganglion of individuals to CGRP actions such as CGRP release and neurogenic inflammation \[[@CR47]\].

The third component of the CGRP receptor, the accessory protein RCP, is required for proper biological function as it is involved in coupling the receptor to downstream signaling pathways like the protein kinase A (PKA) pathway \[[@CR51]\]. Activation of CGRP receptors in cultured trigeminal ganglion cells increased the cAMP levels, which in turn led to elevated CGRP promoter activity and increased CGRP mRNA levels. These results point to an autoactivation of CGRP expression and indicate that elevated release of CGRP in the trigeminal system may create a self-sustaining feedback loop \[[@CR47]\].

CGRP receptor antagonists olcegepant and MK-0974 {#Sec7}
================================================

The excellent correlation between CGRP release and migraine headache has long pointed towards the potential usefulness of a specific CGRP receptor antagonist in the treatment of primary headaches \[[@CR9], [@CR52]\]. Thus, a series of small molecule CGRP receptor blockers were developed. Among those is olcegepant, which demonstrates extremely high affinity for human CGRP receptors, even higher affinity than the endogenous ligand \[[@CR53]\]. Therefore it was selected for further pharmacological investigations. Olcegepant was shown to be a pure antagonist for the human CGRP receptor and to be selective against a broad panel of enzymes and receptors such as calcitonin, amylin or adrenomedullin receptors \[[@CR54]\].

In isolated human temporal, middle meningeal and cerebral arteries olcegepant effectively inhibits CGRP induced dilatation \[[@CR44], [@CR55]\]. That may be due to the block of the CGRP receptor as mRNA for CLR and RAMP1--3 has been found in human middle meningeal arteries, cerebral arteries as well as in microvessels \[[@CR56]\] and CGRP receptor components could be detected in the human cerebral vasculature \[[@CR43]\]. In addition, olcegepant dose-dependently inhibited vasodilatation induced by electrical stimulation of the trigeminal ganglion in primates \[[@CR54]\].

One major advantage of a CGRP receptor blocker is the lack of vasoconstrictor ability. But blockade of the receptor of a strong vasodilatation involves a theoretical risk of causing both peripheral and cerebral vasoconstriction, especially as high affinity binding sites for CGRP have been reported in the heart, liver, spleen, intestine, urogenital system, skeletal muscles, and the skin \[[@CR57]--[@CR59]\]. But olcegepant in doses up to 10 mg did not cause any clinical relevant changes of vital signs like blood pressure and pulse rate, in the ECG or in forearm blood flow in healthy volunteers \[[@CR60]\]. Detailed studies of peripheral arteries such as mesenteric and coronary arteries \[[@CR44], [@CR61]\] revealed that those arteries show weaker responses to CGRP and lower degree of antagonism by olcegepant. This is possibly related to a lower number of CGRP receptors. In addition, a study with seven healthy volunteers disclosed that olcegepant had no influence on cerebral blood flow or on the blood flow velocity in the middle cerebral artery \[[@CR62]\]. It was concluded that CGRP receptor blockade has no effect on the cerebral circulation in man.

However, it is still not clear where olcegepant acts as a CGRP antagonist. It has been reported to inhibit (1) dilatation of dural arteries initiated by CGRP \[[@CR63]\], (2) CGRP-induced hypotension \[[@CR40]\], and (3) increase in facial blood flow after trigeminal ganglion stimulation \[[@CR54]\]. In contrast, olcegepant did not significantly inhibit changes in tone of cerebral arterioles or of local cortical cerebral blood flow \[[@CR40]\]. Those results indicate that olcegepant poorly penetrates the blood-brain barrier, but is very effective in preventing vasodilatation of vessels without this feature \[[@CR64]\]. Thus, this CGRP receptor blocker was suggested to exert its antagonistic effects mainly extracerebral, which correlates with results from a study of healthy volunteers \[[@CR65]\]. In contrast, it was recently shown that CGRP-induced relaxation of the rat middle cerebral artery can only be inhibited by abluminally administered olcegepant as olcegepant was prevented from reaching the CGRP receptors by the arterial endothelium \[[@CR66]\]. These results suggest that the anti-migraine effect of this CGRP receptor blocker is on the abluminal side of the blood-brain barrier. This is supported by the fact that olcegepant only has an antimigraine effect in high doses.

Anyhow, olcegepant was effective in a dose of 2.5 mg in the treatment of acute migraine attacks \[[@CR41]\]. The overall treatment effect revealed a responder rate (a moderate to severe headache going to mild or no headache) of 60% at 2 h after the start of the infusion compared with 27% in the placebo group (Fig. [2](#Fig2){ref-type="fig"}). Thus, intravenous olcegepant was found to be as efficacious as oral sumatriptan in the relief of acute attacks of migraine \[[@CR42]\]. Fig. 2The anti-migraine effect of the CGRP receptor antagonists *MK-0974* and olcegepant and the triptans rizatriptan and sumatriptan compared to placebo at 2-h pain relief. The overall treatment effect of *MK-0974* (*p* = 0.015) and rizatriptan (*p* = 0.010) showed significance versus placebo (*left part*) \[[@CR69]\]. A dose of 2.5 mg of olcegepant also showed significant superiority over placebo (*p* = 0.001) \[[@CR41]\]. Data of sumatriptan from another study \[[@CR42]\] were added to demonstrate the similar efficacy of olcegepant compared to triptans

Significant superiority over placebo was seen regarding the pain-free rate at 2 h, the sustained pain relief at 24 h and the improvement of nausea, photophobia and phonophobia (Fig. [3](#Fig3){ref-type="fig"}). The response was still rising at 4 h pointing at a long duration of action. At 24 h the pain-free rate was better than with triptans, suggesting a lower grade of rebound. Fig. 3Comparison of the sustained pain free-rate at 24 h of the CGRP receptor antagonists *MK-0974* and olcegepant, the triptans rizatriptan and sumatriptan, and placebo. *MK-0974* displayed superior efficacy versus placebo (*p* \< 0.001) \[[@CR69]\]. In order to compare the efficacy of olcegepant to a triptan, data of sumatriptan from another study \[[@CR42]\] were added

The rate of recurrence was 19% as compared to a placebo rate of 46%. This is clearly lower than the recurrence rate of triptans which usually is around 28% \[[@CR42]\].

Safety and tolerability studies also showed that olcegepant is well tolerated. Adverse events were, in general, minor and dose-dependent. Transient mild paresthesia was the single most frequent adverse event \[[@CR60]\].

One major disadvantage of olcegepant remains in its structure. It is a hydrophilic molecule, has poor penetration across the blood-brain barrier and is not suitable as an oral drug. Considering the crucial advantages of an oral formulation of a drug, a small-molecule, non-peptide CGRP antagonist called MK-0974 was recently developed for the acute treatment of migraine attacks \[[@CR67]\]. MK-0974 was, among others, tested in a noninvasive pharmacodynamic model in rhesus monkeys, in which endogenous CGRP release and a vasodilatatory response are achieved by topical application of capsaicin to the forearm of the rhesus monkey \[[@CR68]\]. Infusion of different CGRP receptor antagonists inhibited the increase in local dermal blood flow and showed effectiveness with MK-0974 being the most potent among them (\>3.5-fold) \[[@CR67]\]. In addition, MK-0974 displayed a low clearance (7.0 mL min^−1^ kg^−1^) and a good i.v. half-life (2.8 h). The compound was finally chosen as a clinical candidate, when it showed \>10,000-fold selectivity in assays including more than 160 receptors, transporters, and enzymes \[[@CR67]\].

Recently, MK-0974 has been tested in a randomized, double-blind, placebo-and active-controlled, outpatient study with a two-stage, dose-ranging design to test safety and effectiveness \[[@CR69]\]. Three hundred and thirty patients suffering from migraine with and without aura were treated with MK-0974 (in doses of 25--600 mg), rizatriptan (10 mg) or placebo. As doses below 300 mg were insufficient, they were discontinued. Thus, the overall treatment effect was defined as the average of the 300, 400, and 600 mg doses and showed significance vs. placebo on the primary endpoint (*p* = 0.015), which was defined as pain relief at 2 h after treatment (Fig. [2](#Fig2){ref-type="fig"}).

MK-0974 displayed also superior efficacy vs. placebo for secondary endpoints such as pain freedom at 2 h (overall treatment effect *p* \< 0.001), sustained pain relief at 24 h (overall treatment effect *p* \< 0.001) or sustained pain freedom at 24 h (overall treatment effect *p* \< 0.001) (Fig. [3](#Fig3){ref-type="fig"}). In addition, MK-0974 provided relief of migraine-associated symptoms such as photophobia, phonophobia and nausea.

Rizatriptan (10 mg) was used as an active control and demonstrated effectiveness vs. placebo (*p* = 0.010) on the primary endpoint defined as pain relief at 2 h. By comparison, 300 and 600 mg doses of MK-0974 appeared to work as well as rizatriptan or showed even numerical superiority regarding the sustained pain freedom at 24 h and the sustained pain relief at 24 h.

Concerning tolerability and safety, MK-0974 was generally well-tolerated. The reported side effects were mainly nausea, dizziness and somnolence, but the incidence of adverse experiences seemed to be comparable to the placebo group. In addition, there was no increase in adverse events with increasing dose.

Thus, MK-0974 showed only mild side effects, but significant relief of migraine pain 2 h after treatment compared to placebo and the relief was sustained through 24 h \[[@CR69]\].

Conclusion {#Sec8}
==========

The novel CGRP receptor antagonists appear to be effective in the treatment of moderate and severe migraine attacks. They do not only provide pain relief at 2 h, but also show efficacy regarding the secondary endpoints such as pain freedom, improvement of associated symptoms and functional disability \[[@CR41], [@CR69]\]. In addition, they show a prolonged effect of action compared to the triptans. That may suggest not only less rebound headache but perhaps also a prophylactic possibility. Furthermore, only minor adverse effects were reported and no cardiovascular side effects could be seen so far. This is probably due to the absence of vasoconstrictor properties and it also suggests that vasoconstriction is not necessary to abort acute migraine attacks. This lack of direct vasoconstrictor activity may represent an important advantage over the triptans. Further development of drugs against the CGRP receptor will offer a new promising way of treatment.
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